Related Experiment Videos
Cytotoxic agents in the era of molecular targets and genomics
1Massachusetts General Hospital, Boston, Massachusetts 02114, USA. bchabner@partners.org
Abstract:
Cancer treatment is evolving due to the development of molecularly targeted agents and the utilization of pharmacogenomics and pharmacogenetics to identify patients who are at an increased risk for toxicity or may be uniquely responsive to cytotoxic therapies. By identifying polymorphisms in the human genome that confer changes in the ability to metabolize or activate cancer agents, a more patient-specific treatment approach can be initiated. Molecularly targeted therapies such as PS-341, flavopiridol, Iressa, and anti-vascular endothelial growth factor antibodies may help to overcome resistance to cytotoxic therapies by lowering the apoptotic threshold and increasing cytotoxicity. Using molecularly targeted agents in combination with traditional cytotoxic agents may increase the percentage of patients who achieve disease stabilization and prolonged survival. With the development of genetic tools and genotyping of tumor and patient prior to initiating treatment, antitumor efficacy may be increased with a substantial reduction in toxicity.
Insights
Personalized cancer treatments leverage pharmacogenomics to tailor therapies, improving efficacy and reducing side effects. Identifying genetic variations helps predict patient response to targeted and cytotoxic agents for better outcomes.
Area of Science:
- Oncology
- Pharmacogenomics
- Molecular Biology
Background:
- Cancer treatment is advancing with molecularly targeted agents.
- Pharmacogenomics and pharmacogenetics identify patients at risk for toxicity or with unique responses to therapies.
- Genetic variations influence the metabolism and activation of cancer drugs.
Purpose of the Study:
- To explore the role of molecularly targeted therapies in overcoming resistance to traditional cytotoxic agents.
- To highlight the potential of patient-specific treatment approaches using genetic information.
- To demonstrate how genetic tools can enhance antitumor efficacy and reduce toxicity.
Main Methods:
- Identification of human genome polymorphisms affecting drug metabolism and activation.
- Utilization of molecularly targeted agents (e.g., PS-341, flavopiridol, Iressa, anti-VEGF antibodies).
- Application of genetic tools and genotyping for patient and tumor analysis prior to treatment.
Main Results:
- Molecularly targeted therapies can lower the apoptotic threshold and increase cytotoxicity.
- Combining targeted agents with cytotoxic agents may improve disease stabilization and survival rates.
- Genetic profiling can lead to increased antitumor efficacy and reduced toxicity.
Conclusions:
- Pharmacogenomic approaches enable personalized cancer treatment strategies.
- Molecularly targeted therapies offer a promising avenue to overcome treatment resistance.
- Genomic analysis prior to treatment can optimize therapeutic outcomes and minimize adverse effects.